试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-19
Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery
编号:NCT02276911登记状态:提前终止企业 / 申办者:St. Joseph's Hospital and Medical Center, Phoenix
药物 / 成分:Ibuprofen、normal saline
登记的停止原因(原文):No enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-19
Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study
编号:NCT02531295登记状态:提前终止企业 / 申办者:University of California, San Francisco
药物 / 成分:Euphorbia kansui extract powder prepared as tea
登记的停止原因(原文):Pause on clinical trial enrollment due to grant funding cuts after COVID-19
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-19
Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation
编号:NCT03474614登记状态:提前终止企业 / 申办者:St. Joseph's Hospital and Medical Center, Phoenix
药物 / 成分:Propranolol、DNA and RNA Analysis
登记的停止原因(原文):lack of accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-19
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
编号:NCT03784222登记状态:提前终止企业 / 申办者:Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
药物 / 成分:Blonanserin、MRI and serum BDNF
登记的停止原因(原文):Company's business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-19
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
编号:NCT03801525登记状态:提前终止企业 / 申办者:TG Therapeutics, Inc.
药物 / 成分:Ublituximab、Umbralisib、Venetoclax
登记的停止原因(原文):Strategic/Business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-19
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine
编号:NCT05213143登记状态:提前终止企业 / 申办者:Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
药物 / 成分:Lurasidone
登记的停止原因(原文):Company's business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-18
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
编号:NCT03311334登记状态:提前终止企业 / 申办者:Sumitomo Pharma America, Inc.
药物 / 成分:DSP-7888 Dosing Emulsion、Nivolumab、Pembrolizumab
登记的停止原因(原文):Sponsor's decision to terminate development of the program.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-18
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
编号:NCT03396471登记状态:提前终止企业 / 申办者:Hoosier Cancer Research Network
药物 / 成分:Pembrolizumab、External Beam Radiation Therapy
登记的停止原因(原文):Study failed to meet its interim analysis endpoint
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-18
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
编号:NCT03448692登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:PF-06730512
登记的停止原因(原文):The study was terminated due to lack of efficacy at both tested doses on 5th December 2022. The decision to terminate the study is not related to a safety concern.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-18
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
编号:NCT03608020登记状态:提前终止企业 / 申办者:BioMimetix JV, LLC
药物 / 成分:BMX-001、Whole Brain Radiation Therapy
登记的停止原因(原文):Cessation of grant funding
查看官方原始记录 ↗